http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-071570-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e0bf0928b608797b70bbc2b91c7e52e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N43-78 |
| filingDate | 2009-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-071570-A1 |
| titleOfInvention | PESTICIDE ACTIVE MIXTURES THAT INCLUDE AMINOTIAZOLINE COMPOUNDS |
| abstract | The use of these mixtures to combat insects, accharides, or nematodes, and a method to treat, control, prevent or protect animals against infestation or infection by parasites, using these mixtures. Claim 1: Pesticide mixtures characterized in that they comprise as active compounds 1) at least one aminothiazoline compound 1 of formula 1 wherein R1 is selected from hydrogen, COCH3, COCH2CH3 or COCH2C (CH3) 3; R2 and R3 together with the carbon atom of the phenyl ring to which a ring is attached, which, depending on the tautomere formula 1 a) or b) represents: a benzene ring, a saturated carbocycle of 5, 6 or 7 members, a partially unsaturated carbocycle of 5, 6 or 7 members, a saturated heterocycle of 5, 6 or 7 members, a partially unsaturated heterocycle of 5, 6 or 7 members, whose heterocycles contain 1, 2, or 3 heteroatoms selected from O, S and N as ring members, or a 5 or 6 membered heteroaromatic ring, containing 1, 2, or 3 heteroatoms selected from O, S, and N as ring members, and where the ring, which R2 and R3 together form with the carbon atom of the phenyl ring to which they are attached, is unsubstituted or can carry any combination of 1, 2, 3 or 4 radicals selected from the group consisting of halogen, CH3, CH2CH3, CF3, CH3O, cyano and (= O) (oxo); R4 is selected from hydrogen, fluoro, chloro, bromo, CF3, CH3O or CH3; R5, R6 are selected from hydrogen, chlorine, fluoro, bromine, CH3, CH3O or CF3, where at least one of the radicals R5 or R6 is not hydrogen; it being necessary that R2 and R3 do not together form a group -OCH2-O- or a group -OCF2O; or the tautomers, enantiomers, diastereomers or salts thereof, and 2) at least one active compound II selected from group A formed by A.1 Acetylcholine esterase inhibitors selected from triazamate or from the class of carbamates comprising aldicarb, alanicarb, benfuracarb, carbaryl, carbofuran, carbosulfan, methiocarb, methylthio, oxamyl, pyrimicarb, propoxur and thiodicarb or of the class of the organophosphates comprising acetate, azinfos-ethyl, azinfos-methyl, chloretoxyphos, chlorphevinphos, chlorphenosphos, coumafos, demetone-S-methyl, diazinone, dichlorvos / DDVP, dichrotophos, dimethoate, disulfotone, EPN, ethiona, ethoprophos, famphur, fenamiphos, fenitrotione, fentione, isoxationa, malationa, methamidaphos, metidathione, mevinphos, monochromate methyl, parathion, parathion-methyl, fentoate, forate, phosalone, phosmet, phosphamidone, pyrimiphos-methyl, quinalfos, terbufos, tetrachlorvinfos, trichlorfone triazophos, and vamidotione; A.2 GABA gate chloride channel antagonists selected from cyclodiene organochlorine endosulfan, chlordane, lindane, or N-ethyl-2,2-dimethylpropionamido-2- (2,6-dichloro-alpha, alpha, alpha-trifluoro -p-tolyl) hydrazone or N-ethyl-2,2-dichloro-1-methylcyclopropane-carboxamido-2- (2,6-dichloro-alpha, alpha, alpha-trifluoro-p-tolyl) hydrazone or class of the phenylpyrazole comprising acetoprol, ethiprole, fipronil, pyrafluprol, pyriprole, vanyliprole and the phenylpyrazole compound of formula (3); A.3 Sodium channel modulators selected from the pyrethroid class comprising acrinatrin, aletrin, d-cis-trans-aletrine, d-trans-aletrine, biphentrine, bioaletrine, bio-altrin S-cyclopentenyl, bioresmethrin, cycloprotrin, ciflutrin, beta-ciflutrin, cyhalotrine, gamma-cyhalotrine, lambda-cihalotrine, cypermethrin, alpha-cypermethrin, beta-cypermethrin, zeta-cypermethrin, kyphhenotrine, deltamethrin, empentrine, sphevalerate, etofenprox, fluvatrine, fluvatin, fluvatin, fluvatin halfenprox, imiprotrin, permethrin, phenotrin, praletrin, proflutrin, pyrethrin (pyrethrum), resmethrin, silafluophen, teflutrin, tetramethrin, transflutrin and tralometrine; A.4 Agonists / antagonists of nicotinic acetylcholine receptors selected from nicotine, bensultap, cartap hydrochloride, thiosultap-sodium or thiocyclam or selected from the class of neonicotinoids comprising acetamiprid, clotianidine, dinotefuran, imidacloprid, nitenpyram, and thiacloxamide -1022; or selected from spinosad and spinetoram allosteric nicotinic acetylcholine receptor agonists; A.5 Chloride channel activators selected from abamectin, emamectin benzoate, lepimectin or milbemectin; A.6 Mimics of juvenile hormones selected from hydroprene, kinoprene, phenoxycarb or pyriproxyphene; A.7 Compounds that affect oxidative phosphorylation selected from azocyclotin, cyhexatin, diafentiurone, fenbutatin oxide, propargite or chlorphenapir; A.8 Chitin biosynthesis inhibitors selected from buprofezin or from the benzylurea class comprising bistriflurone, chlorfluazurone, diflubenzurone, flucycloxurone, flufenoxurone, hexaflumurone, lufenurone, noviflumurone, novaluronone tefluburone, and tefluburone; A.9 Mold disruptors selected from ciromazine or from the ecdisone agonist class comprising methoxyphenozide, tebufenozide and azadirachtin; A.10 Mitochondrial electron transport inhibitors selected from phenazaquine, fenproximate, pyrimidiphene, pyridabeno, tolfenpirad flufenerim and rotenone; A.11 Voltage-dependent sodium channel blockers selected from indoxacarb or metaflumizone; A.12 Lipid synthesis inhibitors selected from spirodiclofen, spiromesifene or spirotetramate; A.13 Fumigants: methyl bromide, chloropicrin sulfuryl fluoride; A.14 Selective nutrition blockers: crilotine, pimetrozin, flonicamide; A.15 Mite growth inhibitors: clofentezine, hexithiazox, ethoxazole; A.16 Octapaminergic agonists: amitraz; A.17 Ryanodine receptor modulators: flubendiamide; (R) -, (S) - 3- Chloro-N1- {2-methyl-4- (1,2,2,2-tetrafluor-1- (trifluoromethyl) ethyl] phenyl} -N2- (1-methyl- 2-Methylsulfonylethyl) phthalamide (A17.1); A.18 Antanylamides: chlorantraniliprol, ciantranyliprol, [4-cyano-2- (1-cyclopropyl-ethylcarbamoyl) -6-methyl-phenyl] -amide of 5-bromo-2 acid - (3-Chloro-pyridin-2-yl) -2H-pyrazol-3-carboxylic acid (A.18.1); [2-Chloro-4-cyano-6- (1-cyclopropyl-ethylcarbamoyl) phenyl] -amide acid 5-Bromo-2- (3-chloro-pyridin-2-iI) -2H-pyrazol-3-carboxylic (A.18.2), [2-bromo-4-cyano-6- (1-cyclopropyl-ethylcarbamoyl) - 5-Bromo-2- (3-chloro-pyridin-2-yl) -2H-pyrazol-3-carboxylic acid (A18.3), [2-bromo-4-chloro-6- (1 5-Bromo-2- (3-chloro-pyridin-2-yl) -2H-pyrazol-3-carboxylic acid (A18.4), [2,4-dichloro-] -cyclopropyl-ethylcarbamoyl) -phenyl] -amide 6- (1-Cyclopropyl-ethylcarbamoyl) -phenyl] -amide of 5-bromo-2- (3-chloro-pyridin-2-yl) -2H-pyrazole-3-carboxylic acid (A18.5), [4- 5-Bromo-2- (3-chloro-pyridin-2-yl) -2 H -pyrazine chloro-2- (1-cyclopropyl-ethylcarbamoyl) -6-methyl-phenyl] -amide ol-3-carboxylic (A18.6); A.19 Microbial disruptors: Bacillus thuringiensis subsp. Israelensi, Bacillus sphaericus, Bacillus thuringiensis subsp. Aizawai, Bacillus thuringiensis subsp. Kurstaki, Bacillus thuringiensis subsp Tenebrionis; A.20, a group of different compounds comprising aluminum phosphide, amidoflumet, benzoximate, biphenazate, borax, bromopropylate, cytomethionate, cyanide, clofentezine, cynopyrphene, ciflumetophen, dicofol, ethoxazole, flonicamide, flupirazophos, fluoroxyacetate, hexitraxyacetate, phosphoxacetate, hexitraxyacetate, phosphoxacetate, hexitrate, phosphoxacetate, hexitrate, phosphoxacetate, hexitrexyacetate, phosphokoxacetate, hexitroacetate , sulfoxaflor, pimetrozin, pyridalyl, pyrifluquinazone, 4-but-2-inyloxy-6- (3,5-dimethyl-piperidin-1-yl) -2-fluoro-pyrimidine (A20.1), 3-benzoylamino-N- [2,6-dimethyl-4- (1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl) -phenyl] -2-fluoro-benzamide (A20.2), 4- [5- (3,5 -dichloro-phenyl) -5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl] -2-methyl-N-pyridin-2-ylmethyl-benzamide (A20.3), 4- [5- (3, 5-Dichloro-phenyl) -5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl] -2-methyl-N- (2,2,2-trifluoro-ethyl) -benzamide (A20.4), 4 - [5- (3,5-Dichloro-phenyl) -5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl] -2-methyl-N-thiazol-2-ylmethyl-benzamide (A20.5), 4- [5- (3,5-Dichloro-phenyl) -5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl] -2-methyl-N- (tetrahydro-furan-2-ylmethyl) -be nzamide (M A20.6), 4 - {[(6-bromopyrid-3-yl) methyl] (2-fluoroethyl) amino) furan-2 (5H) -one (A20.7), 4 - {[(6 -fluoropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one (A20.8), 4 - {[(2-chloro1,3-thiazolo-5-yl) methyl ] (2-fIuoroethyl) amino} furan-2 (5H) -one (A20. 9); 4 {[(6-chloropyrid-3-yl) methyl] (2-fluoroethyl) amino} furan-2 (5H) one (A20.10); 4 {[(6.chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one (A20. 11), 4 - {[(6-chloro-5-fluoropyrid-3- il) methyl] (methyl) amino) furan-2 (5H) -one (A20.12); 4 - {[(5 6-dichloropyrid-3-yl) methyl] (2-fluoroethyl) amino} furan-2 (5H) -one (A20.13); 4 - {[(6-chloro-5-fluoropyrid-3-yl) methyl] (cyclopropyl) amino} furan-2 (5H) -Ona (A20.14), 4 - {[(6-chloropyrid-3-yl ) methyl] (cyclopropyl) amino} furan-2 (5H) -one (A20.15); 4 - {[(6-chloropyrid-3-yl) methyl] (methyl) amino} furan-2 (5H) -one (A20.16), cyclopropanoacetic acid, 1,1 '- [(3S, 4R, 4aR, 6S, 6aS, 12R, 12aS, 12bS) -4 - [[(2-cyclopropylacetyl) oxy] methyl-1,3,4,4a, 5,6,6a, 12, 12a, 12b-decahydro-12-hydroxy- 4,6a, 12b-trimethyl-11-oxo-9- (3-pyridinyl) -2H, 11H-naphtho [2,1-b] pyrano [3,4-e) pyran-3,6-diyl] ester ( A20.17), 8- (2-cyclopropylmethoxy-4-methyl-phenoxy) -3- (6-methyl-pyridazin-3-yl) -3-azabicyclo [3.2.1] octane (A20.18), in synergistically effective amounts. |
| priorityDate | 2008-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 248.